Proteomics Expert Says Technology Lags Corporate Promises | GenomeWeb

PHILADELPHIA, May 17 – Many proteomics companies are promising more than they can deliver because they don’t yet have the technology to isolate and characterize low abundance proteins, Ian Humphery-Smith, a protein chemist at the University of Utrecht and the organizer of the Human Proteome Organization, said Thursday.

While companies, such as Large Scale Biology and Myriad, have touted the ability of their technology to pick out most of the proteins in certain cells, they haven’t identified more than five percent of the proteins in the human body, Humphery-Smith said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.